What should I tell an anesthesiologist or procedural team about my GLP-1 medication
Two hormonal pathways, one care plan, titrated to you
L.VaseL.CawcuttK
Not peptides, but commonly offered alongside them Under FDA review BPC-157, TB-500, KPV, MOTS-C on the July 2026 agenda DSIP, Semax, Epitalon on the July 2026 agenda GHK-Cu second review by Feb 2027 CJC-1295 and Ipamorelin were declined in 2024 and remain restricted, not coming back via this process
The field is very close to making some really good headway in metabolic disease, but now you have so many startups seeing how well Ozempic is doing and saying, This is just like Ozempic. Its really not. Some of the alternative supplement purveyors themselves say they agree that the two are not really comparable
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise